

## Disclosures

### Personal Commercial (6)

| Company Name                  | Relationship Category  | Compensation Level       | Topic Area(s)                      |
|-------------------------------|--|--------------------------|------------------------------------|
| <i>Self</i>                   |  |                          |                                    |
| Abiomed                       | Consultant Fees/Honoraria  | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Boston Scientific Corporation | Consultant Fees/Honoraria  | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Getinge                       | Consultant Fees/Honoraria  | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| NuPulseCV                     | Consultant Fees/Honoraria  | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Occlutech                     | Data Safety Monitoring Board   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Verantos                      | Research/Research Grants<br>‡ This was a pilot study involving electronic health records at my institution for which I received a research grant.. | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (2)

| Trial Name   | Trial Sponsor | Trial Funding Source |
|--------------|---------------|----------------------|
| CLASP IIF    | Edwards       |                      |
| PROACTIVE-HF | Endotronix    |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

| Year        | Case Title                         | Represented  | Description  | Compensation       |
|-------------|------------------------------------|--|--|--------------------|
| <i>Self</i> |                                    |  |  |                    |
| 2019        | Complications of cardiogenic shock | Defendant<br>‡ CAPPLIS, CONNORS, CARROLL & ENNIS, PC | A patient presented with cardiogenic shock and had complications related to treatment. | Modest (< \$5,000) |

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 1/15/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 1/15/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 1/15/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 1/15/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.